XBiotech (XBIT) Assets Average (2015 - 2026)
XBiotech (XBIT) posted quarterly Assets Average of $161.3 million for Q4 2025, down 21.14% year-over-year from $204.5 million in Q4 2024, and down 8.15% quarter-over-quarter from $175.6 million in Q3 2025.
XBiotech (XBIT) Assets Average (2015 - 2026) Analysis & Trends
XBiotech's Assets Average history runs 11 years deep, the most recent figure standing at $161.3 million for Q4 2025.
- In Q4 2025, Assets Average fell 21.14% year-over-year to $161.3 million; the TTM figure through Dec 2025 stood at $161.3 million (down 21.14% YoY), while the FY2025 annual figure was $174.6 million, down 17.98% from the prior year.
- Assets Average for Q4 2025 stood at $161.3 million, down from $175.6 million in the prior quarter.
- The five-year high for Assets Average was $354.9 million in Q2 2021, with the low at $161.3 million in Q4 2025.
- The 5-year median for Assets Average is $235.5 million (2023), against an average of $243.5 million.
- Peak annual rise in Assets Average reached 1.01% in 2021, while the deepest fall reached 39.61% in 2021.
- XBiotech's Assets Average stood at $277.3 million in 2021, then dropped by 10.41% to $248.5 million in 2022, then dropped by 8.19% to $228.1 million in 2023, then retreated by 10.36% to $204.5 million in 2024, then declined by 21.14% to $161.3 million in 2025.
- Business Quant data shows XBIT's Assets Average at $161.3 million in Q4 2025, $175.6 million in Q3 2025, and $180.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | XBiotech | 69.51 Mn | 69.51 Mn | - | 141.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 141.87 Mn |
| Dec 31, 2025 | 161.25 Mn |
| Sep 30, 2025 | 175.55 Mn |
| Jun 30, 2025 | 180.27 Mn |
| Mar 31, 2025 | 190.48 Mn |
| Dec 31, 2024 | 204.47 Mn |
| Sep 30, 2024 | 212.70 Mn |
| Jun 30, 2024 | 221.71 Mn |
| Mar 31, 2024 | 227.24 Mn |
| Dec 31, 2023 | 228.11 Mn |
| Sep 30, 2023 | 232.37 Mn |
| Jun 30, 2023 | 238.63 Mn |
| Mar 31, 2023 | 244.11 Mn |
| Dec 31, 2022 | 248.47 Mn |
| Sep 30, 2022 | 258.65 Mn |
| Jun 30, 2022 | 268.63 Mn |
| Mar 31, 2022 | 272.99 Mn |
| Dec 31, 2021 | 277.35 Mn |
| Sep 30, 2021 | 316.74 Mn |
| Jun 30, 2021 | 354.95 Mn |